- Home
- KURA vs MLTX Comparison
KURA vs MLTX Comparison
Compare KURA & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KURA | MLTX |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 972.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KURA | MLTX |
|---|---|---|
| Price | $9.91 | $13.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $25.00 | ★ $36.33 |
| AVG Volume (30 Days) | 1.6M | ★ 1.9M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,029,000.00 | N/A |
| Revenue This Year | $138.16 | N/A |
| Revenue Next Year | $67.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.41 | $5.95 |
| 52 Week High | $12.49 | $62.75 |
Technical Indicators
Market Signals| Indicator | KURA | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 39.89 | 45.56 |
| Support Level | $10.17 | $13.87 |
| Resistance Level | $10.78 | $15.40 |
| Average True Range (ATR) | 0.60 | 0.92 |
| MACD | -0.22 | 0.05 |
| Stochastic Oscillator | 9.47 | 26.83 |
Price Performance
Historical ComparisonAbout KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.